




Medicines & Healthcare products  
Regulatory Agency

# Rules and Guidance for Pharmaceutical Distributors 2022



**PP**  
Pharmaceutical Press



# Contents

Future UK rules and guidance	x
Preface to the 2022 edition	xi
Acknowledgements	xiii
Feedback	xiv
Introduction	xv
Glossary of UK Legislation	xvii

## **Medicines and Healthcare Products Regulatory Agency 1**

<b>1 Medicines and Healthcare Products Regulatory Agency</b>	<b>3</b>
Medicines and Healthcare products Regulatory Agency	3
About the Medicines and Healthcare products Regulatory Agency	3
How we Operate	4
Our responsibilities	5
Compliance	6
Compliance Teams and Applications and Registrations	6
Applications and Registrations	9
Defective Medicines Report Centre (DMRC)	11
Criminal Enforcement Unit	13
Compliance Management and Inspection Action Group	14
Advice	20

## **Wholesale Distribution of Medicines 23**

### **2 UK Legislation on Wholesale Distribution 25**

The Human Medicines Regulations 2012 [SI 2012/1916]	25
---	----



<b>3 EU Guidelines on GDP and UK Guidance on Wholesale Distribution</b>	<b>53</b>
Introduction	57
Chapter 1 – Quality Management	57
UK Guidance on Chapter 1 – Quality Management	59
Chapter 2 – Personnel	70
UK Guidance on Chapter 2 – Personnel	72
The Responsible Person Gold Standard	77
The Responsible Person (Import)	84
Chapter 3 – Premises and Equipment	89
UK Guidance on Chapter 3 – Premises and Equipment	93
Short-Term Storage of Ambient and Refrigerated Medicinal Products – Requirements for a Wholesale Dealer's Licence	102
Chapter 4 – Documentation	102
UK Guidance on Chapter 4 – Documentation	104
Data Integrity	107
Chapter 5 – Operations	114
UK Guidance on Chapter 5 – Operations	118
Parallel Importation	128
Products Imported from Countries on a List	130
What evidence can be used for independent batch release certification?	132
Continued Supply	133
Integration Operational Processes to Mitigation of Risk of Theft or Diversion of Medicine	138
Sourcing and Exporting Medicinal Products – non-EEA Countries	140
Controls on Certain Medicinal Products	151
Sales Representative Samples	159
Diverted Medicines	160
Chapter 6 – Complaints, Returns, Suspected Falsified Medicinal Products and Medicinal Product Recalls	160
UK Guidance on Chapter 6 – Complaints, Returns, Suspected Falsified Medicinal Products and Medicinal Product Recalls	163
Handling Returns	163
Falsified Medicines	165
Reporting Adverse Reactions	167



Product Recall/Withdrawal	167
Chapter 7 – Outsourced Activities	175
UK Guidance on Chapter 7 – Outsourced Activities	176
Chapter 8 – Self-inspections	177
UK Guidance on Chapter 8 – Self-inspections	177
Chapter 9 – Transportation	179
UK Guidance on Chapter 9 – Transportation	181
MHRA expectations in regard to control and monitoring of temperature during transportation	181
Other guidance – United Kingdom exit from the European Union, and Northern Ireland	190
Sourcing medicines for the UK market	192
Guidance and useful resources	198
The Application and Inspection Process: “What to Expect”	202
Risk-based Inspection Programme	206
Conditions of Holding a Wholesale Dealer’s Licence	207
Matters Relating to Unlicensed Medicines	217
<b>Brokering of Medicines</b>	<b>219</b>
<b>4 UK Legislation on Brokering Medicines</b>	<b>221</b>
The Human Medicines Regulations 2012 [SI 2012/1916]	221
<b>5 EU Guidelines on GDP and UK Guidance on Brokering Medicines</b>	<b>227</b>
Introduction	227
Chapter 10 – Specific Provisions for Brokers	228
UK Guidance on Chapter 10 – Specific Provisions for Brokers	229
Additional UK Guidance	234
Provision of Information	236
Management of Recall Activity by Brokers	236
<b>Manufacture, Importation and Distribution of Active Substances</b>	<b>239</b>
<b>6 UK Legislation on the Manufacture, Importation and Distribution of Active Substances</b>	<b>241</b>
The Human Medicines Regulations 2012 (SI 2012/1916)	241
Chapter 1a Good Manufacturing Practice and Good Distribution Practice	243



<b>7</b>	<b>Guidelines of 19 March 2015 on Principles of Good Distribution Practice of Active Substances for Medicinal Products for Human Use (2015/C 95/01)</b>	<b>252</b>
	Introduction	252
	Chapter 1 – Scope	253
	Chapter 2 – Quality System	253
	Chapter 3 – Personnel	254
	Chapter 4 – Documentation	254
	Chapter 5 – Premises and Equipment	256
	Chapter 6 – Operations	256
	Chapter 7 – Returns, Complaints and Recalls	259
	Chapter 8 – Self-Inspections	260
	Annex - Glossary of terms applicable to these guidelines	261
<b>8</b>	<b>UK Guidance on the Manufacture, Importation and Distribution of Active Substances</b>	<b>263</b>
	Introduction	263
	Registration	264
	Conditions of Registration as a Manufacturer, Importer or Distributor of an Active Substance	268
	GMP for Active Substances	271
	GDP for Active Substances	271
	Written Confirmation	272
	Template for the “written confirmation” for active substances exported to the European Union for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC	273
	<b>Appendices</b>	<b>285</b>
	<b>Appendix 1</b>	<b>287</b>
	Human and Veterinary Medicines Authorities In Europe	287
	<b>Appendix 2</b>	<b>293</b>
	List of Persons Who Can be Supplied with Medicines by way of Wholesale Dealing (Human Medicines Regulations 2012)	293
	All Medicines	293
	Pharmacy Medicines	294

General Sale List Medicines	294
Other Relevant Provisions	294
Additional Provisions for Optometrists and Dispensing Opticians not Included in Schedule 17	295
Schedule 17 Exemption for Sale, Supply or Administration by Certain Persons	296
<b>Appendix 3</b>	<b>313</b>
<b>Sources of Useful Information</b>	<b>313</b>
<b>Appendix 4</b>	<b>315</b>
<b>Importation of Active Substances for Medicinal Products for Human Use – Questions and Answers</b>	<b>315</b>
<b>Appendix 5</b>	<b>323</b>
<b>Safety Features for Medicinal Products for Human Use – Questions and Answers</b>	<b>323</b>
<b>Index</b>	<b>359</b>